Cagrilintide + Tirzepatide
Also known as: Cagri + Tirz · CagriTirz
A combination of the long-acting amylin analog cagrilintide with the dual GLP-1/GIP agonist tirzepatide, discussed together in the context of appetite and weight regulation.
Class
Amylin analog + GLP-1/GIP agonist blend
Default unit
mg
Common route
Subcutaneous
Typical half-life
Long-acting (both components multi-day)
Frequency
Once weekly
Commonly associated areas
Illustrative map of the body systems Cagrilintide + Tirzepatide is most often discussed in relation to. Relative emphasis only — not a measure of efficacy or a medical claim.
Proposed mechanisms / pathways
What is Cagrilintide + Tirzepatide?
Cagrilintide + Tirzepatide is a combination of two distinct long-acting molecules discussed together. Cagrilintide is an amylin analog — amylin is a hormone co-released with insulin that signals fullness — while tirzepatide is a dual GLP-1/GIP receptor agonist of the same incretin family as other weekly metabolic agents. Pairing an amylin analog with an incretin agonist is an approach studied for its complementary effects on appetite and weight.
How it is thought to work
The two parts are thought to act on different but overlapping appetite systems. Tirzepatide is proposed to engage the GLP-1 and GIP pathways that influence satiety, gastric emptying, and blood-sugar handling, while cagrilintide is thought to add amylin signaling associated with fullness after eating. Combining them is studied on the idea that the pathways may reinforce one another. These mechanisms remain under investigation and are not settled.
Educational only — not medical advice
This combination is discussed for research and educational interest and is not an approved, packaged product for general human use. Nothing here is a recommendation, dose, or medical claim — consult a qualified healthcare provider before considering any protocol.
Tracking Cagrilintide + Tirzepatide in LynkDose
Because this pairs two long-acting agents that are usually titrated over weeks, careful record-keeping makes patterns visible. In LynkDose, log each weekly administration with its date, note when either component’s amount changes, keep a consistent weekly weigh-in, and record appetite and any gastrointestinal effects. Over time that history lets you connect changes in weight or tolerability to a specific step rather than guessing.
Commonly discussed for
- Appetite and craving regulation
- Weight-management research protocols
- Combined incretin and amylin pathway interest
Often stacked: This entry is itself a blend of two compounds — cagrilintide (an amylin analog) and tirzepatide (a GLP-1/GIP agonist) — rather than something typically stacked further.
How to track Cagrilintide + Tirzepatide in LynkDose
Because two long-acting agents are combined and often titrated, log each weekly administration with its date and any dose change, alongside a consistent weigh-in, appetite notes, and any GI effects.
Deeper read: Tracking GLP-1 Peptides (Semaglutide & Tirzepatide)
Not medical advice
This page is educational and does not recommend, prescribe, or dose any compound. Many peptides are research chemicals not approved for general human use. Always consult a qualified healthcare provider and follow the laws in your area.